 |
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2018, vol. 24, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2018241.1883
Published online: 24 January 2018
Original article
J of IMAB. 2018 Jan-Mar;24(1):1883-1886
STUDY OF THE IMMUNOLOGICAL MARKERS CD49d AND CD38 IN EARLY-STAGE B-CLL PATIENTS
Vanya Popova1
, Svetla Blazheva2, Tsvetan Lukanov2, Silvia Naneva1, Nikolay Tzvetkov1,
1) Clinic of Haematology, University hospital, Medical University, Pleven, Bulgaria.
2) Immunological laboratory, University hospital, Medical University, Pleven, Bulgaria.
ABSTRACT:
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B- lymphocytes into the blood stream, primary and secondary lymphoid organs as a consequence of defect in the apoptosis. Most frequently it affects people aged 67- 72. The greater part of CLL patients are in the early stage of the disease at the time of diagnosis, which gives a chance to delay the therapy. In 2008 the diagnostic criteria for CLL were revised. New prognostic and predictive factors were added in order to make the indications for starting the treatment more precise
The aims of our study were: to determine the frequency of monoclonal B-cell lymphocytosis (MBL) in the subjects with absolute lymphocytosis, to establish a relationship between the flow cytometric markers CD49d and CD38 in patients with early stages Rai O-II / Binet A. To distinguish the patients with B- CLL from MBL as well as to define the expression of immunological markers we used flow cytometric analysis of peripheral blood.
The results of our study have shown that a small number of patients met the criteria for MBL. Flow cytometric markers CD49d and CD38 associated with unfavorable prognosis were negative in most of the early stage patients.
Keywords: leukemia, integrin, stage,
- Download FULL TEXT /PDF 688 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Popova V, Blazheva S, Lukanov T, Naneva S, Tzvetkov N. Study of the immunological markers CD49d and CD38 in early-stage B-CLL patients. J of IMAB. 2018 Jan-Mar;24(1):1883-1886.
DOI: 10.5272/jimab.2018241.1883
Correspondence to: Vanya Slavcheva, MD. Clinic of Hematology, University hospital, Medical University Pleven; 8 A, G. Kochev blvd., Pleven 5800, Bulgaria; E-mail: slavcheva05@gmail.com
REFERENCES:
1. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. [PubMed] [CrossRef]
2. Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? Clin Oncol. 2014 Mar 20;32(9):869-72. [PubMed] [CrossRef]
3. Zolatan M. Predicting outcome in CLL: The role of new prognostic markers. Chronic lymphocytic leukemia: New research. 2008. ISBN:978-1-60456-681-7.
4. Nabhan C, Raca G, Wang YL. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era. JAMA Oncol. 2015 Oct;1(7):965-74. [PubMed] [CrossRef]
5. Baumann T, Delgado J, Santacruz R, Martсnez-Trillos A, Rozman M, Aymerich M, et al. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. Br J Haematol. 2016 Jan;172(1):48-55. [PubMed] [CrossRef]
6. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523-31. [PubMed] [CrossRef]
7. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015 Jul 23;126(4):454-62. [PubMed] [CrossRef]
8. Brachtl G, Pinon Hofbauer J, Greil R, Hartmann TN. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol. 2014 Mar;93(3):361-74. [PubMed] [CrossRef]
9. Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood. 2013 Nov 7;122(19):3317-21. [PubMed] [CrossRef]
10. Walsby E, Buggins A, Devereux S, Jones C, Pratt G, Brennan P, et al. Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. Blood. 2014 Jun 5;123(23):3607-17. [PubMed] [CrossRef]
11. Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Del Poeta G, et al. The Role of CD49d in Chronic Lymphocytic Leukaemia: Microenvironmental Interactions and Clinical Relevance. EMJ Hema. 2014 Jul;1:80-87.
12. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nuckel H, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014 Mar 20;32(9):897-904. [PubMed] [CrossRef]
13. Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol. 2010 Dec;20(6):416-23. [PubMed] [CrossRef]
14. Hartman WR, Pelleymounter LL, Moon I, Kalari K, Liu M, Wu TY, et al. CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. Leuk Lymphoma. 2010 Jul;51(7):1315-25. [PubMed] [CrossRef]
15. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011 Sep 29;118(13):3470-8. [PubMed] [CrossRef]
16. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004 Feb 15;103(4):1202-10. [PubMed] [CrossRef]
17. Eichhorst B, Hallek M. Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155. [PubMed] [CrossRef].
Received: 20 June 2017
Published online: 24 January 2018